Duchenne muscular dystrophy
Sqy Therapeutics is focused on clinical research in Duchenne muscular dystrophy, with interest in both paediatric and adult patients carrying a genetically confirmed diagnosis. Its work centres on a neuromuscular disease area marked by progressive muscle weakness and loss of function.
- Neuromuscular disorders
- Inherited muscle disease
- Paediatric and adult care
The sponsor’s research activity is directed toward the clinical understanding of Duchenne muscular dystrophy and related therapeutic needs in a specialised patient population.
Safety and tolerability
Clinical research supported by Sqy Therapeutics includes evaluation of safety and tolerability in patients with Duchenne muscular dystrophy, reflecting a therapeutic interest in treatment acceptability and patient exposure considerations within a rare disease setting.
- Safety assessment
- Tolerability
- Rare disease treatment evaluation
This area of interest aligns with the needs of long-term management in muscle degeneration and supportive therapeutic development.
Pharmacokinetics and pharmacodynamics
The sponsor also investigates pharmacokinetics and pharmacodynamics, indicating a focus on how a therapy is handled by the body and how it affects disease-relevant biological activity in Duchenne muscular dystrophy.
- Drug disposition
- Biological activity
- Mechanism-related assessment
These research interests are relevant to the development of targeted approaches for genetic muscle disorders.
Muscle biopsy and tissue evaluation
Sqy Therapeutics’ clinical programme includes muscle biopsy as part of its research landscape, supporting tissue-level evaluation in Duchenne muscular dystrophy and helping characterise disease-related changes in skeletal muscle.
- Muscle tissue analysis
- Skeletal muscle pathology
- Biological marker assessment
This reflects an interest in the structural and biological features of muscular dystrophy relevant to therapeutic development.
Genetically confirmed patient population
The sponsor’s clinical focus is confined to patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy, underscoring attention to precision-defined enrolment in a rare neuromuscular disease population.
- Genetic confirmation
- Rare disease population
- Specialised neuromuscular care
The research setting is centred on clinically characterised patients with a clear molecular diagnosis.
